J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...

Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve ...

Johnson & Johnson (J&J) has shared positive data from a late-stage study of its subcutaneous CD38-directed antibody Darzalex ...

Although it was receiving revenue from eight products, royalties from Johnson & Johnson (JNJ) subsidiary Janssen’s ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...